Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis.
We treated 22 patients with subacute sclerosing panencephalitis (SSPE) with intraventricular alpha-interferon (IFN) and inosiplex PO and followed them for 2 to 54 months. Three deaths occurred. Clinical improvement, demonstrated by decreasing scores on the Neurological Disability Index, occurred in 11/22 (50%); five patients became stable, and the progression rate of the disease decreased in three. The remission rate was significantly higher than untreated controls from the same institution. Patients who had a slowly progressive disease responded best to treatment. Serious side effects were rare. We recommend intraventricular IFN, combined with oral inosiplex, in the treatment of SSPE.
Yalaz
K
K
Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.
Anlar
B
B
Oktem
F
F
Aysun
S
S
Ustacelebi
S
S
Gurcay
O
O
Gucuyener
K
K
Renda
Y
Y
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D007542:Inosine Pranobex / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*
D016898:Interferon-alpha; D007542:Inosine Pranobex